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Abstract
Rheumatoid arthritis (RA), the commonest inflammatory arthritis, is a 
debilitating disease leading to decreased functional capacity, social disability 
and reduced quality of life. RA affects multisystems with chronic inflammatory 
disease characterized by destructive synovitis and muscular dysfunction leading 
to premature musculoskeletal aging, which has been coined with many terms 
including myopenia, sarcopenia, cachexia, muscle failure and muscle wasting. 
Myopenia is described as the presence of clinically relevant muscle wasting due to 
any illness at any age, associated with impaired muscle function, increased mor-
bidity and mortality. RA myopenia has significantly less muscle mass compared 
to the general population muscle loss showing preservation or slight increase in 
fat mass. RA myopenia is unique compared to chronic disease-related myopenia 
in cancer, chronic heart failure, kidney disease and chronic infection as it is rarely 
accompanied by a net weight loss. RA myopenia has younger-age onset compared 
to elderly primary sarcopenia, while higher-grade inflammation has been consid-
ered as the pathophysiology of muscle wasting. Research, however, indicates that 
inflammation itself cannot fully explain the high prevalence of muscle wasting in 
RA. This chapter aims to review the literature on the casual relationships among 
RA myopenia, premature musculoskeletal aging and management strategies to 
delay musculoskeletal aging.
Keywords: myopenia, rheumatoid arthritis, musculoskeletal aging, chronic 
inflammation
1. Musculoskeletal aging in the healthy elderly
Muscle mass decreases on advancing age with men losing more absolute and 
relative muscle mass, especially most prevalent in the seventh decade and beyond 
[1]. After the age of 50, approximately 1–2% per year of muscle mass is lost, and 
this age-related reduction in muscle mass and strength is accompanied by intramus-
cular fat accumulation, muscle atrophy (especially the type IIa fibers), decreased 
satellite cell proliferation and differentiation capacity, and reduction in motor unit 
quantity. This muscle remodeling results in changes in muscle architecture that 
is believed to play a key role in the loss of muscle force and power characteristic 
of advanced age [2, 3]. Mitchell’s group [1] reported only 0.5–1.0% loss of muscle 
mass per year after 70 and a 4.7% loss compared with peak muscle mass in men and 
3.7% decrease for women per decade. Muscle strength simultaneously declines by 
10–15% per decade up to 70 years of age, while the muscle strength loss accelerates 
to between 25 and 40% per decade [4, 5]. Frailty may be regarded as a condition 
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of transition from health to disability during aging. The concept of frailty is often 
defined as the presence of fatigue, slowness, weakness, low physical activity and 
exhaustion, which are all mainly related to muscle loss [6].
2. Prevalence of musculoskeletal aging in rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by 
erosive arthritis and systemic organ involvement with the worldwide prevalence of 
roughly 5 per 1000 adults. The disease may affect all ages and both sexes; usually, it 
is seen in young women aged 25–45. The peak incidence is in the sixth decade with 
recent studies showing that RA is among the most common inflammatory disease in 
the elderly, accounting for 2% of the geriatric population [7]. The general consensus 
in the literature is defining rheumatoid arthritis onset after 65 years of age being 
known as elderly onset RA (EORA). EORA incidence and prevalence in different 
population-based studies in the world may vary widely, depending on sex and 
ethnicity [8]. One study showed the incidence rate of RA per 100,000 population 
over the age of 60 being 9.1 in men and 14.5 in women [9]. A USA study showed the 
prevalence of RA being 0.5–1%, with 2% in the population over 60 years [10]. The 
UK-based database Norwalk Arthritis Research (NOAR) showed the incidence of 
RA increasing with age [11]. The Chinese pooled prevalence showed the estimated 
population prevalence of RA being 0.37% with 10% elderly onset RA [12]. This 
fact will likely increase the number of patients with EORA in the coming years to 
encourage research into the impact of ethnic and geographic differences on the 
management of RA.
3.  Myopenia, sarcopenia, cachexia, muscle failure and muscle wasting 
disease as one concept in muscle aging of rheumatoid arthritis
3.1 Myopenia and sarcopenia
Myopenia is a relatively new term [13] describing the presence of clinically 
relevant muscle wasting due to any illness and at any age, associated with clinically 
relevant degree of muscle wasting, impaired muscle function and increased risks of 
morbidity or mortality. This term would translate more sufficiently and specifically 
in clinical settings than sarcopenia, which was introduced in 1988 with the original 
definition being a “muscle loss” of the appendicular muscle mass in the older people 
as measured by dual-energy X-ray absorptiometry [14]. In 2010, the European 
Working Group on Sarcopenia for Older Persons recommended a new operational 
definition of sarcopenia of aging (primary sarcopenia) including the presence of 
low muscle mass, low muscle strength and low muscle function and performance 
[15]. In 2018, two pieces of consensus evidences on sarcopenia of aging were 
published to combine the update by the European Working Group on Sarcopenia 
[16] with management of sarcopenia of aging by the International Clinical Practice 
Guidelines for Sarcopenia [17]. The consensus statement confirms the requirements 
of low muscle strength (low muscle quality), low muscle mass (low muscle quan-
tity) and muscle functional impairment (low muscle performance) for the clinical 
diagnosis. Secondary sarcopenia, a similar term to myopenia, is associated with the 
international consensus definitions specific to malignant sarcopenia in the recent 
sarcopenia positional review [18]. There are several points of relevance regarding 
age-related (primary sarcopenia) and disease-related (secondary sarcopenia) loss 
of muscle mass. Loss of appendicular skeletal muscle mass with aging (primary 
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sarcopenia) occurs continuously in the order of ~5% in men and somewhat lower 
in women after reaching peak muscle mass in young adulthood at about 30 years 
of age by a variety of longitudinal observational studies [19, 20]. Another interest-
ing terminology related to secondary sarcopenia is sarcopenic obesity, and the 
copresence of sarcopenia and obesity has been considered a more deleterious body 
composition phenotype [21]. In addition to a myriad of cardio-metabolic outcomes 
related to the effects of fat tissue, higher proportions of fat mass might further 
affect muscle quality and increase the risk of disability and mortality [22]. A recent 
Brazil study [23] concluded sarcopenic obesity, but obesity alone was not associ-
ated with obstructive sleep apnea (OSA). Both obesity and sarcopenic obesity but 
not sarcopenia were associated with nocturnal hypoxemia, suggesting a complex 
pathophysiologic relationship between adverse body composition states and 
OSA. There are cultural difference in sarcopenic obesity with recent published data 
of Chinese RA patients, which indicated the lower prevalence of obesity (Chinese 
4.2% vs. Westerners 21.4–34.7%) and higher prevalence of underweight (Chinese 
17.7% vs. Westerners 1.1–2.2%). Taking together, secondary sarcopenia or myopenia 
has a non-linear muscle loss curve with a considerably greater magnitude than the 
linear curve seen in primary sarcopenia. RA patients have significantly less muscle 
mass compared to the general population, leading to the statement (Figure 1) that 
myopenia is a form of premature disease-related muscular aging in association 
with connective tissue diseases like rheumatoid arthritis and other chronic diseases 
shown in Figure 1.
Figure 1. 
Myopenia in association with connective tissue diseases like rheumatoid arthritis and other chronic diseases.
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3.2 Cachexia, muscle failure and muscle wasting disease
Rheumatoid arthritis cachexia (RAC) is characterized by high degrees of muscle 
mass loss and muscle strength loss, associated with preservation or slight increase 
in fat mass [24]. RAC is unique in comparison to other forms of cachexia observed 
in cancer, chronic heart failure, kidney disease and chronic infection as it is rarely 
accompanied by a net weight loss [25]. RAC also differs from primary sarcopenia 
in the elderly as it occurs at much younger age associated with significantly higher 
muscle mass loss [26]. Higher-grade inflammation has been considered as the 
central component of the pathophysiology and the key driver of muscle wasting. 
More recent findings, however, indicate that inflammation on its own cannot fully 
explain the high prevalence of muscle wasting in RA. Thus, two lifestyle factors 
including nutrition and physical activity have also been studied to indicate that 
they play a significant role in muscle wasting in RA, but again neither of these 
factors seems to be able to fully explain the condition. Oxidative stress is one of the 
major mechanisms thought to contribute to the development and progression of 
RA, but its potential contribution to muscle wasting in these patients has received 
limited attention. Oxidative stress has been shown to promote muscle wasting in 
healthy populations and people with several chronic conditions. Moreover, all of the 
aforementioned potential contributors to muscle wasting in RA (i.e., inflammation, 
nutrition and physical activity) may promote pro- or anti-oxidative mechanisms. 
Muscle failure is another new term describing the combination of primary and 
secondary sarcopenia, leading to a more relevant functional definition of premature 
muscle aging related to rheumatoid arthritis, RA-related muscle failure instead of 
myopenia. This review will put more emphasis to highlight the important clinical 
implication of myopenia and premature muscular aging and discuss the various 
management strategies of delaying musculoskeletal aging in RA, including muscle 
regeneration via reduction in oxidative stress and early control of inflammation via 
lifestyle and pharmacological interventions.
4. Genetics of RA and muscle aging
RA develops in individuals with a genetic association in RA, which is the pres-
ence of DRB1 locus in the HLA class 2 gene. The RA-associated DRB1 alleles share 
a linear sequence of amino acids between positions 70 and 74 in the HLA-DRB1 
chain of the HLA-DRa/b heterodimer, which has led to the ‘shared epitope’ (SE) 
hypothesis [27], posing a risk factor for RA development. Jnhi DRB1 allele was 
associated with early onset of disease, radiological erosion and extra-articular 
findings [28]. The results of studies investigating genetic predisposition in EORA 
are inadequate and contradictory [29]. RA-associated DRB1 alleles show differ-
ences in early and late onset RA as well as ethnic variants. A Spanish study found 
that YORA was related to DRB1/04, while EORA was associated with DRB1/01 
[30]. This study also found that increased DRB1–13/14 frequency was detected in 
patients with seronegative EORA and polymyalgia rheumatica (PMR). Another 
prospective study established the facts that a relationship was found between PMR 
and DRB1*0101/0102/0401, while seronegative EORA was associated with DRB1-
0401. Kim and colleagues investigated the impact of HLA-DRB1 and HLA-DQB1 
genes on susceptibility to disease and disease severity in EORA and YORA patients 
[31]. Alleles encoding the common epitope were detected less frequently in EORA 
compared with YORA with the effect of the common epitope and HLA-DQ*04 
alleles being shown to be less significant. In comparison with YORA, EORA has also 
been found to have less common epitope presence and less radiological progression. 
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Hellier and colleagues investigated the effect of the HLA-DRB1 gene on disease 
susceptibility and disease severity in EORA and YORA [32] and demonstrated HLA-
DRB1/04-related alleles were not closely associated in EORA. Thus, it is suggested 
that the impact of these genes on the susceptibility to disease in EORA is not very 
important. Wu and colleagues showed that the DRB1/04 allele was detected in half 
of the EORA population, while the DRB1/04 frequency was 92% in patients with 
RA starting before 30 years of age [33].
In terms of genetic contribution and impact on the individual variability in 
muscle aging phenotypes literature on specific gene variants, it remained contro-
versial and no solid evidence exists supporting the existence of an ‘unfavorable’ 
genotype associated with accelerated age-related sarcopenia or loss of independent 
function [34]. Although the ACTN3 R577X polymorphism is the only structural 
gene for which a clear genotype effect has been shown in human muscle pheno-
types, especially for athletic women, there is controversy with regard to which allele 
(R or X) plays a potential ‘favorable’ role in aging. The MSTN K153R variation is 
possibly the strongest candidate to explain variance among muscle phenotypes in 
the elderly, yet more research is still needed with large cohorts owing to the very low 
population frequency of the ‘unfavorable’ 153R allele. Recent evidence [34] indicates 
that age-related declines in muscle phenotypes are likely polygenic traits and thus 
not reducible to specific polymorphisms, suggesting that future studies should con-
sider the association between muscle phenotypes in older people including complex 
gene-gene interactions, interactions between genetic variants that might not influ-
ence muscle phenotypes individually and the interaction between genes and chronic 
disease like rheumatoid arthritis and lifestyle risk factors such as physical activity. 
It is important to determine those genetic factors that interact with aging and thus 
modulate functional capacity and genetic predisposition of myopenia in rheumatoid 
arthritis. It would be also clinically relevant to identify ‘unfavorable’ genotypes 
associated with myopenia in rheumatoid arthritis.
5. Pathogenesis of myopenia and musculoskeletal aging in RA
Two major subtypes of RA are classified according to the presence or absence 
of anti-citrullinated protein antibodies (ACPAs). Citrullination is catalyzed by the 
calcium-dependent enzyme peptidylarginine deiminase (PAD), changing a posi-
tively charged arginine to a polar but neutral citrulline as the result of a post-trans-
lational modification. ACPAs can be detected in approximately 67% of RA patients 
and serve as a useful diagnostic reference for patients with early, undifferentiated 
arthritis and provide an indication of likely disease progression through to RA 
[35, 36]. The ACPA-positive subset of RA has a more aggressive clinical phenotype 
compared to ACPA-negative subset of RA [37]. It is reported that ACPA-negative 
RA has different genetic association patterns [37] and differential responses of 
immune cells to citrullinated antigens [38] from those of ACPA-positive subset. In 
terms of standard treatment [39–41], less effective treatment response of metho-
trexate (MTX) or rituximab was observed in ACPA-negative subset. Future studies 
are needed on the potential pathophysiology difference between the two subsets, 
while this chapter will focus on the ACPA-positive subset of RA and divide the onset 
and progression of RA process into the above-mentioned EORA and YORA. Since 
the clinical, genetic and laboratory differences between EORA and YORA are not 
understood yet, the immunological and hormonal changes in the elderly population 
may be responsible for the physiological process characterized by reduced T-cell 
proliferation, reduced antibody synthesis to vaccination and elevated proinflamma-
tory cytokine levels. Immune system changes include T-cell phenotype alteration, 
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reduction in specific immune response, apoptosis defects, cytokine imbalance and 
inadequate antigen presentation. With increasing age, there is a decrease in the 
protective immunological response, while the reaction to autoantigens is increas-
ing [42]. In addition, self-tolerance mechanism disorders occur. As a result of 
thymus involution in senescence, changes in T-cell composition, decrease in T-cell 
proliferation and cytokine synthesis, as well as decreased antibody synthesis after 
vaccination, were seen. In one study, elevated interleukin (IL)-6 secretion was 
associated with dehydroepiandrosterone and androstenedione synthesis in patients 
with EORA [43]. The acute onset and increased acute phase response seen in EORA 
may be explained by increased IL-6 levels. Punzi and colleagues showed elevated 
IL-6 as acute onset and increased acute phase response in the EORA synovial 
fluid compared with YORA, suggesting the role of IL-6 while no differences were 
detected in IL-1 and IL-8 levels [44]. Different immunoregulatory mechanisms may 
be at work in the pathogenesis of RA seen in different age groups with one study by 
Gamerith and colleagues showing a significantly increased anti-IgG-Fab/free aFab 
ratio in patients with YORA, compared with EORA, leading to increased rheu-
matoid factor (RF) presence [45]. Myopenia in RA will be mediated by a similar 
mechanism of rising IL-6, leading to premature muscle aging in YORA, while 
acute-onset-induced long-term muscle damage is equivalent to premature muscle 
aging in EORA. Further research is required to unlock the mechanism of premature 
muscular aging in RA patients.
6. Clinical features of myopenia in rheumatoid arthritis
Myopenia in rheumatoid arthritis is a similar term to terms described above 
including secondary sarcopenia, rheumatoid arthritis cachexia and muscle failure 
or muscle wasting in rheumatoid arthritis. The clinical features follow the two 
forms of rheumatoid arthritis including EORA and YORA with their distinctive 
features. EORA has three distinct clinical patterns [46] with the most common 
clinical form (70%) displaying RF positivity, joint erosions and worse prognosis 
than YORA, while the second form (25%) is a PMR-like form with proximal limb 
joint involvement characterized by RF negativity, being associated with acute onset, 
lack of joint erosions and good prognosis. Non-erosive polyarthritis may be present 
in 25% of patients with PMR as one of the main differential diagnoses [47]. The 
presence of metacarpophalangeal (MCP)/proximal interphalangeal (PIP) joint 
arthritis with proximal limb joint involvement is considered a predictive factor for 
seronegative EORA. The third EORA pattern is featured by clinical and prognostic 
similarity to RS3PE syndrome [48] with sudden onset, wrist tenosynovitis, com-
mon pitting edema in the hands, HLA-B27 positivity and spontaneous remission 
within 3–18 months. EORA is not limited to the differentiate diagnosis of PMR, 
but also associated with other diseases including crystal arthritis, septic arthritis, 
sarcoidosis and hepatitis C [49]. In many studies [50, 51], simultaneous small and 
large joint involvement is frequently seen at the onset of the disease, while RF and 
anti-CCP positivity are seen at similar and/or slightly lower rates in comparison 
with YORA. Acute onset, PMR-like symptoms, less rheumatoid nodule and RF 
positivity were detected in EORA compared with YORA. Patients with EORA had 
a lower joint score and a higher Health Assessment Questionnaire (HAQ ) score. A 
recent study [52] reported the clinical and demographic characteristics of Turkish 
patients with EORA displaying shoulder joint involvement being more frequent in 
EORA, while PIP, MCP, elbow and ankle joint involvement were more common in 
YORA. RA deformities, Sjögren syndrome (SjS) and lung involvement are less com-
mon in EORA. Weight loss, myalgia, lymphadenopathy and PMR-like symptoms 
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were also more frequent in EORA, while the antibody profile (RF, ANA, anti-Ro 
and anti-La) was detected less frequently in EORA. In contrast, anemia of chronic 
disease, ESR and CRP elevation were more common in a study reported by van der 
Heijde and colleagues [53]. Another aggressive, destructive EORA form of EORA 
having more frequent acute onset, initially small and large joint involvement, PMR-
like patterns and radiological narrowing of the joint space was reported by Lance 
and colleagues with radiographic erosive changes [54]. In this report, the patients 
are characterized by polyarticular small joint involvement, rapid progression, 
hand/wrist erosions and early hand function loss as well as 63% of these patients 
reported secondary SjS compared with 25% in patients with YORA. More recently, 
myopenia has been reported to be very common in Chinese RA patients that is 
associated with functional limitation and joint damage in RA [55]. In another report 
at the 2019 American College of Rheumatology meeting, myopenia, equivalent to 
body composition disorder in elderly Chinese patients with RA, showed that elderly 
female patients with myopenia were associated with severe joint damage in rheuma-
toid arthritis [56]. These studies reflected both the cultural and gender diversity of 
myopenia in RA.
7. Laboratory findings in myopenia in RA
It has been well documented that lower hemoglobin and higher ESR and CRP 
were detected in EORA in comparison with YORA [57]. In some studies, RF and 
anti-CCP antibody positivity were reported less frequently in EORA, while in other 
studies, the frequency of these antibodies was found to be similar in both groups 
[51, 53, 58]. Chen and colleagues compared the pro-inflammatory cytokine levels 
of patients with EORA and YORA [59] demonstrating that higher levels of IL-6 
and lower levels of tumor necrosis factor α (TNFα) were detected in EORA, associ-
ated with higher IL-6 levels being detected in patients with EORA and PMR-like 
symptoms. Multivariate analysis showed that high IL-1 levels were associated with 
anti-CCP antibodies, while high TNFα levels were associated with constitutional 
symptoms in patients with EORA. In comparison with YORA, acute onset, constitu-
tional symptoms and comorbidities were more frequent in patients with EORA.
8. Prognosis of myopenia in RA
There is no direct evidence for discussion with respect to the impact of myopenia 
on the prognosis of RA. The prognosis of RA in terms of RA’s age of onset remains 
unclear with some studies showing EORA with better prognosis compared with 
YORA, while others report that they are similar or worse. The above contradictory 
results may be due to different disease durations between groups examined, bias 
in patient selection, and different frequencies of seropositivity between younger 
and older patients. In one study, persistent arthritis was seen in 39% of seroposi-
tive patients, while in seronegative patients, this rate was only 6% [60]. In another 
study, more swollen joints, radiological damage and mortality were reported in 
seropositive patients in comparison with seronegative patients [61]. In other words, 
RF and anti-CCP antibodies are considered poor prognostic markers in patients 
with EORA. Krams and colleagues compared the characteristics of patients with 
EORA and YORA in the ESPOIR cohort containing 681 patients with RA [62], and 
the one-year remission rates were higher in the patients with YORA than those with 
EORA showing more erosion and high HAQ scores in patients with EORA. As a 
result, at the end of the third year, patients with YORA had higher remission rates, 
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less radiographic progression and lower HAQ scores compared with patients with 
EORA. A Korean study evaluated 3169 Korean patients with RA [58] and showed 
that the 486 patients with RA that started when they were over 60 years old were 
considered to have EORA and it has been found to be an independent risk factor 
for functional disability. In one study, the presence of acute pitting swelling in the 
hands at the onset of the disease was shown to be a good prognostic factor [60] with 
EORA presenting with pitting edema having fewer erosions compared with patients 
with EORA without pitting edema. In terms of EORA mortality related to myope-
nia, there was a statistically significant increase in mortality rates in patients with 
seropositive EORA compared with the general population [57], while there was not 
significant difference in patients who were seronegative.
9. Treatment and management of myopenia in RA
Management of myopenia in RA will translate the latest research evidence of 
treatment strategies for rheumatoid arthritis. These strategies include the optimi-
zation of lifestyle and risk factor modifications including nutrition and exercise; 
pharmacological interventions include early administration of disease-modifying 
antirheumatic drugs (DMARDs); and targeted strategies have been able to prevent 
radiological progression, reduce morbidity and mortality, and increase functional 
capacity [63, 64].
10. Exercise and myopenia/cachexia in rheumatoid arthritis
RA and exercise have been thoroughly reviewed [65] to indicate the reduced 
and compromised exercise capacity in comparison with normal people due to their 
RA manifestations of pain, stiffness, structural joint damage, bone density loss 
and muscle weakness [66, 67]. It is well established that physical exercise programs 
promote prolonged improvements [68] without inducing harmful effects on 
disease activity and joint damage [69]. Recent evidence [65] has examined different 
modalities of exercises including resistance training, aerobic training and combina-
tion of the two modalities. Aerobic training consists of cycling, aquatics, dancing, 
walking and running. The final messages show that exercise is effective in reversing 
joint damage in RA patients as long as RA-specific considerations are being taken 
into account when developing exercise programs aiming to reduce CVD risk and 
improve quality of life and maintaining activity of daily living functions of RA 
patients. In another study [70] describing myopenia/cachexia and exercise types for 
treatment, intensive progressive resistance training (PRT) can increase lean mass, 
reduce fat mass, increase strength and improve function. PRT is the most effective 
exercise to improve skeletal muscle size and strength, even safe when performed 
at high intensity with RA patients. Resistance training increases tendon stiffness 
and strengthens connective tissue, while cyclic loading (e.g., walking, cycling and 
strength endurance exercises) enhances cartilage integrity and joint lubrication as 
well as mobility exercises increase range of motion. In terms of symptom control 
in RA patients, exercise can reduce pain and morning stiffness and even reduce 
fatigue as well as improve functional ability and psychological well-being without 
exacerbating disease activity. The review also discusses the improvement of patient 
perceptions regarding the effects and benefits of exercise, clarifies specific exercise 
recommendations and considers methods of overcoming individual barriers to 
exercise. A recent study showed that hydrotherapy had a positive role in reducing 
pain and improving health status of RA patients [71]. All RA patients should be 
9Myopenia and Musculoskeletal Aging in Rheumatoid Arthritis
DOI: http://dx.doi.org/10.5772/intechopen.91270
encouraged to include some form of aerobic and resistance exercise training as part 
of their routine care. More research is still required on the optimal and individual-
ized frequency, intensity, time and types (FITT model) of exercises, or when it 
requires a combination of types as well as how best to incorporate exercise into the 
lives of RA patients across the variable course of the disease. Large cohort studies 
will be required to examine the potential ethnic differences in terms of myopenia 
and muscle aging in diverse cultures such as in China, India or Africa.
11.  Management of frailty and prefrailty in rheumatoid arthritis 
myopenia
Frailty, which was originally considered a geriatric syndrome [72], is associated 
with reduced muscle strength, exhaustion and high inflammatory markers [73, 74], 
leading to perpetuation of the frailty and prefrailty cycle associated with different 
frailty assessment tools [75, 76]. Frailty and myopenia share a common cardinal 
clinical feature of reduced muscle strength. A recent study [77] showed that frailty 
and prefrailty are common in RA patients of younger age and are more prevalent 
than expected. As the prevalence of frailty increases with age, this study indicates 
that it is important to counteract frailty for the treatment of myopenia in RA 
patients. A very interesting aspect for further research would be to assess the frailty 
status in a large sample size to investigate if the frailty score is lower in RA patients 
who have entered into permanent remission after early treatment, whereby they did 
not develop any joint damage, compared to age- and sex-matched patients who have 
been treated less aggressively.
12. Myopenia, heart failure and premature myocardial aging in RA
RA and other autoimmune chronic inflammatory disorders including psoriasis 
and inflammatory bowel diseases have been well documented to be associated 
with considerably increased cardiovascular morbidity and mortality in compari-
son with the background population [78–82]. In particular, the cardiovascular 
disease risk in RA patients appears to be comparable with that found in type 2 dia-
betes mellitus patients [83–85]. Conventional cardiovascular risk factors including 
hypertension, obesity, dyslipidemia and diabetes mellitus with RA-specific risk 
factor of increased systemic inflammation have been implicated to contribute 
significantly [81, 86].
Heart failure (HF), an alternative term describing myopenia in the cardiac 
muscle, has been shown by numerous public health studies to be associated with 
increased inflammation and a high prevalence of cardiovascular risk factors [87, 
88]. The proinflammatory cytokines of HF promote myocardial damage leading to 
myopenia of cardiac muscle and other pathogenic manifestations through an array 
of mechanisms including increased arterial stiffness and endothelial dysfunction 
[89–95]. A number of review and population studies have examined the risk of 
developing HF in RA patients and found that RA-specific HF can be independent 
of cardiovascular risk factors [89, 93, 96, 97]. One of the commonest risk factors 
and potential cause of HF is ischemic heart disease, which was not shown to be 
responsible for the increased risks of HF in rheumatoid arthritis. This paper [93] 
also demonstrated that the increased risks of non-ischemic HF in RA presented 
early in association with RA severity. A more recent Danish cohort study [98] aimed 
to investigate the risk of incident HF in RA patients indicated that rheumatoid 
arthritis was associated with a 30% increased hospitalization for heart failure in 
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comparison with the general population. The clinical Implications of these findings 
add to the existing evidence that rheumatoid arthritis may be a clinically relevant 
risk factor for heart failure and premature cardiac muscle aging in RA patients. 
Future studies examining the value of more extensive screening of RA patients for 
heart failure are warranted.
In terms of the potential mechanism for increased risks of HF in early course 
of RA, RA has been associated with left ventricular concentric remodeling and 
systolic and diastolic left ventricular dysfunction [89, 90, 93, 97]. RA patients are 
more likely to display significantly elevated levels of circulating cardiac biomark-
ers including troponins, pro-B-type natriuretic peptides, which are recognized 
as important prognostic markers of cardiac diseases, especially HF [99]. Thus, 
it is highly conceivable that chronic systemic inflammation in RA may confer 
an increased risk of HF and premature myocardial aging that is independent of 
traditional cardiovascular risk factors.
13. Myopenia and pharmacological intervention in RA
Delaying myopenia and premature muscle aging in RA patients is closely 
related to the age of onset and preclinical staging of RA. While there are no direct 
evidences specifically evaluating the impact of pharmacological interventions 
including synthetic DMARDS and biologics on the management of myopenia in 
RA, the European League Against Rheumatism guideline advocates early aggressive 
treatment with these synthetic DMARDS and biologics via their direct effect on 
reducing inflammation for the purpose of reducing myopenia, delaying premature 
muscle aging in RA and decreasing cardiovascular morbidity and mortality in RA 
[100, 101]. These agents are also expected to exert their benefits via their direct 
effect on reducing inflammation, subsequently improving joint inflammation and 
function and potentially leading to increased levels of physical activity with conse-
quent reduction of other risk factors including diabetes mellitus and hypertension 
[100, 101]. A recent study also demonstrates the potential mechanism of how 
synthetic DMARDS and biologics reduce the risks of sudden cardiac death in RA 
patients [100].
Identifying a preclinical stage and a growing understanding of the natural 
history and mechanisms of RA development, alongside new potential pharmaco-
logical interventions, shape the prospect that myopenia with premature muscle 
aging in RA might be preventable in future [102]. The current treatment principles 
for established RA involve symptomatic management and disease modification. 
A meta-analysis of 12 published studies confirmed that patients receiving delayed 
DMARDs therapy were at higher risk of developing radiographic joint space 
narrowing and bony erosions [103] associated with myopenia in RA with a recent 
cross-sectional study [55]. In poorly controlled RA patients, bony erosions become 
more pronounced on radiographs within 2 years of onset and these erosive changes 
are predictive of poorer functional outcome [104]. In a patient with otherwise 
unexplained new onset polyarthritis, an urgent referral to a rheumatologist is thus 
mandatory to confirm an RA diagnosis and early initiation of a DMARDs-based 
treatment plan aiming for disease remission with delaying myopenia in RA and pre-
venting deformity. Oral corticosteroids are potent and effective anti-inflammatory 
drugs that may contribute to disease modification [105] to delay myopenia and pro-
mote healthy aging. However, this needs to be weighed up against its well-known 
adverse effects of osteoporosis. Symptomatic management remains the cornerstone 
interventions throughout the course of the disease with everyday practical measures 
to deal with the primary symptoms of joint stiffness including pain and fatigue via 
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the mechanism of reducing systemic inflammation. This chapter is not for detailed 
review and discussion of the pharmacological intervention of RA but endeavors to 
provide a table from the main author’s previous review to summarize the modern 
pharmacological therapies for RA (Table 1) [106].
Table from Ref. [106]. Permission from Bone Research is pending.
Table 1. 
Modern pharmacologic therapies for rheumatoid arthritis.
Rheumatoid Arthritis
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In terms of the age of onset of rheumatoid arthritis, the ultimate goal of RA 
treatment including EORA and YORA is to control the disease, delay myopenia 
and maintain functional capacity. As discussed above on genetics, clinical 
features, pathogenesis and prognosis of EORA and YORA, treatment of EORA 
should not be so different from treatment of YORA. The goal of treatment 
should be complete remission or low disease activity based on the principles of 
treat-to-target strategies. DMARDs used in YORA may also be safely used in the 
treatment of EORA as long as drug pharmacokinetics and pharmacodynamics 
in the elderly can be clinically considered with closely monitoring the drug side 
effect profile [107]. EORA has more comorbid diseases and high number of 
medications used and consequently increasing drug-drug interactions exac-
erbating the potential side effect profile [108]. DMARDs used in patients with 
EORA are limited and contradictory and are receiving less aggressive treatment 
based on data from patients with EORA in the CORONA database in compari-
son with those of age- and sex-matched patients with YORA [109]. The study 
[109] also showed that disease activity and disease severity were similar in both 
groups. Methotrexate (MTX) use was found to be higher in patients with EORA 
compared with those with YORA (63.9% vs. 59.6%), while mean MTX dose 
was found to be higher in patients with YORA. The number of patients using 
multiple conventional DMARDs or biological DMARDs was found to be lower in 
those with EORA compared with YORA. Treatment-related toxicity was similar 
in both groups, whereas toxicity due to MTX was found to be more frequent in 
the case of YORA. Despite similar disease duration, disease activity and sever-
ity, patients with EORA used combined conventional DMARDs and biological 
DMARDs less frequently compared with patients with YORA. It has been well 
documented that the age of onset determines the severity of the disease and 
the choice of treatment [110]. According to Swiss registries, the use of fırst-
line corticosteroids was significantly higher in patients with EORA compared 
with those with YORA, in contrast to the much lower follow-up on the use of 
biological drugs [111]. Genevay and colleagues evaluated 1571 patients with RA 
receiving anti-TNFα drugs [112] and demonstrated similar changes with drug 
withdrawal rates and mean Disease Activity Score (DAS28) score changes in 
both groups at the end of the second year. Despite clinical responses, improve-
ment in Health Assessment Questionnaire (HAQ ) scores was significantly less 
in patients with EORA. TNF inhibitors were slightly less or equally effective 
in reducing disease activity in elderly compared with younger patients with 
HAQ scores showing less improvement in patients with EORA, especially in 
patients aged over 75 years [113]. There is limited evidence for the effectiveness 
of tocilizumab, abatacept, rituximab and tofacitinib in EORA. Tocilizumab was 
less effective in EORA compared with YORA, while the drug retention rate and 
discontinuation rates because of adverse events were similar between the two 
age groups [114]. There is no data on abatacept in EORA, while RCTs showed 
tofacitinib to be similarly effective in both EORA and YORA [115]. In terms of 
myopenia in both EORA and YORA, a recent study [116] indicates that EORA is 
characterized by more equal distribution of sex, higher frequency of acute onset 
with constitutional symptoms, more frequent involvement of large joints, and 
lower frequency of RF positivity. Earlier diagnosis, less erosive disease and less 
DMARD usage were reported as distinguishing patients with EORA from those 
with YORA. Further studies require the exploration of myopenia and its severity 
and impact on the prognosis of RA including both EORA and YORA, reflecting 
the above-mentioned concepts of secondary sarcopenia, cachexia and frailty 
with old age, potentially impacting RA prognosis in the presence of DMARD 
side effects.
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14. Conclusion and future perspectives
Myopenia and premature muscular aging in RA are similar concepts, raising a 
lot of research questions in terms of mechanism, lifestyle intervention, comorbidity 
management and new pharmacological approach. The chapter provides the plat-
form for a discussion about the new term of myopenia and its impact.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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